BioTuesdays

Category - Features

Transition moves into late-stage drug development

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a...

Alpha Cancer to test oncology game changer

Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug candidate, ACT...

Advaxis readies cervical cancer pivotal trial

Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the encouraging...

In conversation with Michael Vidne

As director of business development for closely held NovellusDx, Michael Vidne has an enviable position in one of the hottest areas of health care: personalized medicine. A former consultant in the West Coast Office of...

Venaxis pivotal APPY1 data due in March

Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a final data package...

In conversation with Elias Vamvakas

As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab...

Encision to launch simplified AEM device

The new management team at Encision (OTC:ECIA) plans to launch in late spring a simplified version of its Active Electrode Monitoring (AEM) technology, known as the EndoShield Burn Protection System, to continuously...

Alcobra’s ADHD program moving to pediatrics

With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric ADHD program...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.